Skip to main content

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

Written by Customer Service on . Posted in Public Companies.

– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –

SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) — Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced they will host an investor webcast on Tuesday, October 13 at 4:30 p.m. ET. On the call, management from the companies will provide details regarding the formation of Caspian and will also review KO-7246 data featured in an oral presentation at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting.

Virtual Investor Event

Caspian and Kura management will host a webcast and conference call on October 13, 2026 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast and replay will be available on www.kuraoncology.com under the Investors tab in the Events and Presentations section.

About Caspian Therapeutics

Caspian Therapeutics is pioneering menin-directed therapies in diabetes and other cardiometabolic diseases. Built on more than a decade of menin-inhibitor research at Kura Oncology, Caspian combines deep expertise in menin biology and medicinal chemistry with a development strategy focused on the requirements of diabetes and other cardiometabolic diseases.

Caspian’s lead compound, KO-7246, is a next-generation, highly selective and orally bioavailable menin inhibitor intended for metabolic applications and is currently in IND-enabling development. Caspian plans to evaluate KO-7246 in a Phase 1 program designed to assess its potential to restore functional β-cell capacity and endogenous insulin production in patients with diabetes. Caspian also plans to advance a second development candidate for additional cardiometabolic indications. To learn more, visit www.caspiantherapeutics.com. 

About Kura Oncology

Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small-molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Contacts
Caspian Therapeutics
Robert Spencer, Ph.D.
rob@caspiantx.com 

Kura Oncology
Greg Mann
858-987-4046
gmann@kuraoncology.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.